News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Health & Biotech
Dimerix to progress DMX-200 to phase 3 trial to treat kidney disease FSGS
Health & Biotech
ScoPo’s powerplays: It’s been ‘like a waterfall of information’ hitting us daily
News
ASX stocks in America: Opthea’s about to join the ranks but who’s there already?
News
Rise and Shine: What you need to know before the ASX opens
News
These 18 ASX stocks have gained over 1,000 per cent in 6 years
Health & Biotech
Dr Boreham’s Crucible: Kazia reaches the ‘endgame’
Guides
The 100 best performing ASX stocks in FY20
Experts
Scopo’s health powerplays: Get ready for the pullback
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Check up: Sometimes no news is good news
Health & Biotech
What’s Opthea eyeing now that it has two successful trials under its belt?
Health & Biotech
Opthea’s done it again: Its drug passed its DME clinical trial
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Clock’s Ticking: In 24 hours we’ll know if Opthea’s DME clinical trial was successful
Experts
Scopo’s health powerplays: You’re all going to the pot, literally
Health & Biotech
We’re still here: investors keen on health despite market shun
Health & Biotech
